Market Overview

Alexion Says Clinical, Statistical Improvement in 2nd Endpoints of Eculizumab Study

Related ALXN
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Alexion Announces Study Presented at ASN 2015 Supports Effectiveness of Soliris in Preventing TMA Events in Patients with aHUS

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented data from a single-arm, open-label, investigator-initiated Phase 2 study of eculizumab (Soliris^®) as an investigational therapy in 14 patients with severe, relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The study met its primary efficacy endpoint with high degrees of clinical and statistical significance. Clinically and statistically significant improvements were also observed in key secondary endpoints. Data were presented today at a Scientific Symposium Oral Session at the American Neurological Association annual meeting in Boston, Mass.^1

Posted-In: News FDA


Related Articles (ALXN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters